Form 4: Integrated BioPharma CFO Exercises Stock Options, Acquires 65,000 Shares

Integrated BioPharma's Chief Financial Officer, Dina Masi, exercised stock options to acquire 65,000 shares of common stock at $0.09 per share.

Summary

• Dina Masi, the Chief Financial Officer of Integrated BioPharma Inc., exercised stock options on November 25, 2024.
• This transaction resulted in the acquisition of 65,000 shares of common stock at a price of $0.09 per share.
• Following the transaction, Ms. Masi directly owns 212,200 shares of common stock.
• The stock options exercised were granted on June 2, 2015, and were set to expire on June 2, 2025.

Sentiment

Score: 6

Explanation: The document reflects a routine transaction, with no significant positive or negative implications. It is a neutral event.

Positives

• The exercise of stock options by a key executive can be seen as a positive sign of confidence in the company's future prospects.

Industry Context

This is a routine transaction for a company with stock option plans, and is common in the biotechnology industry.

Comparison to Industry Standards

• Stock option exercises are a common form of compensation for executives in publicly traded companies, particularly in the biotech sector.
• The exercise price of $0.09 per share is not unusual for companies with stock option plans, and is often set at the market price at the time of the grant.
• The number of shares acquired, 65,000, is not unusual for a CFO level executive.

Stakeholder Impact

• The transaction has a minor positive impact on shareholders as it shows confidence from the CFO in the company's future.

Key Dates

Keywords

stock options, insider trading, share acquisition, common stock, Integrated BioPharma, Dina Masi, CFO